Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | MYC | P01106 | 2/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16252831 | 0.84 | TLR8 (0.61) | TDP1TLR8 | |
| SCHEMBL9279114 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1TDP1TLR8NR4A3 | |
| SCHEMBL7303862 | 0.78 | NR4A3 (0.48) | KDM4EALDH1A1TDP1TLR8NR4A3 | |
| SCHEMBL25367626 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1TDP1TLR8NR4A3 | |
| SCHEMBL1290821 | 0.76 | NR4A3 (0.42) | KDM4EALDH1A1TDP1TLR8NR4A3 | |
| SCHEMBL21863437 | 0.75 | DRD2 (0.41) | KDM4ETLR8SSTR4 | |
| SCHEMBL359062 | 0.74 | KDM4E (0.57) | KDM4EALDH1A1TDP1TLR8HSD17B10 | |
| SCHEMBL23109051 | 0.73 | DRD2 (0.50) | KDM4EALDH1A1TLR8SSTR4RAB9A | |
| Butane SCHEMBL8878913 | 0.73 | FNTA (0.48) | KDM4EALDH1A1TLR8FNTAFNTB | |
| SCHEMBL19456728 | 0.72 | SLC22A12 (0.41) | KDM4ETLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-10071974-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-11 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-9789082-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-01-19 | — | — | US | disclosed |
| US-9371282-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140343065-A1 | New Somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-5200415-A | Serotonin receptor antagonists; antiemetics, antianxietics | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0483836-A1 | Pyrazolo [1,5-a] pyridine-3-carboxylic acid derivatives, their preparation process and their use | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071974-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR1, SSTR3 | KDM4E 1147/4885ALDH1A1 2546/4885TDP1 3829/4885 |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | KDM4E 2536/4885ALDH1A1 3117/4885TDP1 3431/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | KDM4E 3565/4885ALDH1A1 587/4885TDP1 1095/4885 |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR1, SSTR3 | KDM4E 1147/4885ALDH1A1 2546/4885TDP1 3829/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | KDM4E 3143/4885ALDH1A1 4740/4885TDP1 2107/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALDH1A1 344/4885TDP1 1309/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALDH1A1 344/4885TDP1 1309/4885 |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | KDM4E 2413/4885ALDH1A1 2901/4885TDP1 3674/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885ALDH1A1 312/4885TDP1 1034/4885 |
| US-20140343065-A1 | New Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | KDM4E 2413/4885ALDH1A1 2901/4885TDP1 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.